Lupin Income Statement | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Lupin Ltd.

Lupin Ltd. | Income Statement

Fiscal year is April-March. All values INR Millions.

2014

2015

2016

2017

2018

Sales/Revenue

110,859

125,989

137,819

170,091

155,509

Cost of Goods Sold (COGS) incl. D&A

66,586

66,400

70,659

86,288

94,740

Gross Income

44,273

59,589

67,159

83,802

60,769

SG&A Expense

16,602

26,844

36,494

48,379

40,479

EBIT

26,508

31,580

18,628

Unusual Expense

411

111

14,550

Non Operating Income/Expense

2,313

2,529

849

2,992

3,037

Interest Expense

253

419

1,398

1,879

Pretax Income

28,317

34,148

33,239

35,349

5,433

Income Tax

9,622

9,704

10,593

9,785

2,885

Equity in Affiliates

Consolidated Net Income

18,695

24,444

22,695

25,646

2,584

Net Income

18,364

24,032

22,607

25,575

2,513

Net Income After Extraordinaries

18,364

24,032

22,607

25,575

2,513

Net Income Available to Common

18,364

24,032

22,607

25,575

2,513

EPS (Basic)

40.99

53.54

50.23

56.69

5.56

Basic Shares Outstanding

448

449

450

451

452

EPS (Diluted)

40.79

53.20

49.93

56.46

5.54

Diluted Shares Outstanding

450

452

453

EBITDA

29,118

35,927

37,487

42,666

29,487

Other Operating Expense

1,162

1,165

1,950

1,880

1,662

Non-Operating Interest Income

159

131

169

196

Minority Interest Expense

331

412

About Lupin

View Profile

Address	B/4 Laxmi Towers Mumbai Maharashtra 400051 India
Employees	-
Website	http://www.lupinworld.com
Updated	09/14/2018
Lupin Ltd. engages in the manufacture of pharmaceutical products. Its offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments.